Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Four Firms Vie For Medicare 2014 New-Tech Add-On Payments

This article was originally published in The Gray Sheet

Executive Summary

CMS held its annual new-technology Town Hall Feb. 5, hearing from applicants for a drug-eluting peripheral artery stent, a neurostimulator system for epilepsy seizures, a transcatheter mitral valve repair system and a retinal prosthesis system.

You may also be interested in...



Medicare Bonus Payments Awarded To Cook’s Stent, Second Sight’s Eye Implant

Cook Medical’s Zilver PTX stent and Second Sight Medical Products’ Argus II retinal prosthesis system will enjoy new-technology add-on payments in 2014 under CMS’ hospital inpatient prospective payment system final rule.

Medicare Bonus Payments Awarded To Cook’s Stent, Second Sight’s Eye Implant

Cook Medical’s Zilver PTX stent and Second Sight Medical Products’ Argus II retinal prosthesis system will enjoy new-technology add-on payments in 2014 under CMS’ hospital inpatient prospective payment system final rule.

FDA Advisors Vote That Benefits Of Abbott’s MitraClip Outweigh Risks

The agency’s Circulatory System Devices Panel narrowly voted in favor of Abbott’s MitraClip transcatheter mitral valve repair system to reduce mitral regurgitation. But the discussions about the clinical evidence on the technology were complex and the panel’s support for Abbott’s PMA was not unanimous.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT032719

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel